drugset / Trial / NCT06834100

Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

NCT06834100

Phase 3 Recruiting 240 enrolled NPO Petrovax
RandomizedParallel-groupSingle-blindPrevention

Summary

Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug

Timeline

Start
2025-02-12
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GNG-DE Unknown 0.5 ml Intramuscular
Subject Menactra Vaccine 0.5 ml Intramuscular